CDK6 and acute myeloid leukemia: Given the confirmed TKi activity of narazaciclib against CSF1R, FLT3 and CDK6 above and its impact on the proliferation of CSF1R- or FLT3-ITD/TKD-driven recombinant cells, we next tested the anti-AML activity of narazaciclib.